IBI-3002 Drug Asset Due Diligence Report 2026

This IBI-3002 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether IBI-3002 can convert its Bispecific antibody profile and IL-4Rα x TSLP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	IBI-3002 (query alias: IBI-3002)
Modality / target	Bispecific antibody; IL-4Rα x TSLP; IL-4Rα inhibitors, TSLP inhibitors
Highest global status	Phase 2
Originator	Innovent Biologics (Suzhou) Co. Ltd.
Active developers	Innovent Biologics (Suzhou) Co. Ltd.

The MCP disease footprint includes Moderate Atopic Dermatitis, Severe Atopic Dermatitis, Asthma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07399067	Phase 2	Recruiting	120	Primary endpoint not disclosed in English source
NCT07015762	Phase 1	Recruiting	9	Primary endpoint not disclosed in English source
NCT07015749	Phase 1	Recruiting	12	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

B32-36 IBI3002, A First-in-class Anti-IL-4RΑ/TSLP Bispecific Antibody in Patients With Mild-To-Moderate Asthma: A Randomized, Double-Blind, Placebo-Controlled, Single Dose Phase Ib Study

Phase 1; n=8; evaluation: Positive. Reported fields: TEAE = Two participants receiving IBI3002 reported treatment-emergent adverse events: one with presyncope and sciatica, and another with back pain and ecchymosis, of which only ecchymosis was assessed as related to treatment. All TEAEs were mild in severity. ; TEAE = Two participants receiving IBI3002 reported treatment-emergent adverse events: one with presyncope and sciatica, and another with back pain and ecchymosis, of which only ecchymosis was assessed as related to treatment. All TEAEs were mild in severity.

Preclinical Characterization of IBI3002, an Anti-IL-4Rα and Anti-TSLP Bispecific Antibody That Potently Dampens Inflammatory Response and Alleviates Asthma in Mice

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: Comparative in-vivo activity = at lower drug exposure, IBI3002 demonstrates comparable in-vivo activity to Dupilumab and Tezepelumab, whose exposure was 4 to 9 times higher than that of IBI3002 individually

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

IBI-3002 addresses Moderate Atopic Dermatitis, Severe Atopic Dermatitis, Asthma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 16 matched transaction record(s) under the scope “target-level comparable: IL-4Rα x TSLP.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-4Rα x TSLP records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-09-02	Keymed licenses approved IL-4Ralpha mAb stapokibart to Singapore firm Aeira for 18 Asian markets	Approved	Financial terms not disclosed
2025-01-24	Transaction title not available in English source	Phase 3	Financial terms not disclosed
2024-11-18	Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets	Preclinical	US$40.0M upfront; US$900.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treating post-covid airway disease”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO